Wedbush Reiterates Outperform on Arcus Biosciences, Maintains $30 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Robert Driscoll has reiterated an Outperform rating on Arcus Biosciences (NYSE:RCUS) and maintained a $30 price target on the stock.

May 09, 2024 | 12:50 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst Robert Driscoll reaffirmed an Outperform rating on Arcus Biosciences and maintained a $30 price target.
The reiteration of an Outperform rating and maintenance of a $30 price target by a reputable analyst like Robert Driscoll from Wedbush is likely to instill confidence among investors and could positively influence Arcus Biosciences' stock price in the short term. Analyst ratings, especially from well-regarded financial institutions, can significantly impact investor sentiment and stock prices.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100